Cargando…
The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma
BACKGROUND: Patients face increasing insurance restrictions on prescription drugs, including generic-only coverage. There are no generic inhaled corticosteroids (ICS), which are a mainstay of asthma therapy, and patients pay the full price for these drugs under generic-only policies. We examined cha...
Autores principales: | Fung, Vicki, Tager, Ira B, Brand, Richard, Newhouse, Joseph P, Hsu, John |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2488344/ https://www.ncbi.nlm.nih.gov/pubmed/18638405 http://dx.doi.org/10.1186/1472-6963-8-151 |
Ejemplares similares
-
Inhaled Corticosteroids and Adult Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2019) -
Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis
por: Henkle, Emily, et al.
Publicado: (2022) -
COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial
Effect of Inhaled Corticosteroids?
por: Maes, Tania, et al.
Publicado: (2020) -
Inhaled Corticosteroids in Asthma and the Risk of Pneumonia
por: Kim, Min-Hye, et al.
Publicado: (2019) -
Asthma and Therapeutics: Inhaled Corticosteroids, Corticosteroid Osteoporosis, and the Risk of Fracture in Chronic Asthma
por: Toogood, John H
Publicado: (2005)